Antihepatitis <scp>B</scp> therapy: a review of current medications and novel small molecule inhibitors

Qiu, Lipeng; Chen, Liang; Chen, Keping

doi:10.1111/fcp.12053

Cited by 17 publications

(14 citation statements)

References 163 publications

(257 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that AS‐IV exerts potent anti‐HBV activity. AS‐IV not only could inhibit the HBsAg expression and the HBeAg secretion in HeG 2 2.2.15 cells, but also reduce the level of DHBsAg in DHBV‐infected ducks .…”

Section: Pharmacological Effect Of Astragaloside IVmentioning

confidence: 97%

Research review on the pharmacological effects of astragalosideIV

Hou²,

Rongfang³

et al. 2016

Fundamemntal Clinical Pharma

278

176

View full text Add to dashboard Cite

Astragalus membranaceus Bunge has been used to treat numerous diseases for thousands of years. As the main active substance of Astragalus membranaceus Bunge, astragaloside IV (AS-IV) also demonstrates the potent protective effect on focal cerebral ischemia/reperfusion, cardiovascular disease, pulmonary disease, liver fibrosis, and diabetic nephropathy. Based on studies published during the past several decades, the current state of AS-IV research and the pharmacological effects are detailed, elucidated, and summarized. This review systematically summarizes the pharmacological effects, metabolism mechanism, and the toxicity of AS-IV. AS-IV has multiple pharmacologic effects, including anti-inflammatory, antifibrotic, antioxidative stress, anti-asthma, antidiabetes, immunoregulation, and cardioprotective effect via numerous signaling pathways. According to the existing studies and clinical practices, AS-IV possesses potential for broad application in many diseases.

show abstract

Section: Pharmacological Effect Of Astragaloside IVmentioning

confidence: 97%

Research review on the pharmacological effects of astragalosideIV

Hou²,

Rongfang³

et al. 2016

Fundamemntal Clinical Pharma

278

176

View full text Add to dashboard Cite

show abstract

“…The number of HBV-related targets used for antiviral interventions is very limited. Currently available anti-HBV drugs are (i) the nucleoside/nucleotide analogs (entecavir, lamivudine, adefovir dipivoxil, tenofovir and telbivudine) that target only the reverse transcription; and (ii) versions of interferon alpha (including alpha-2b interferon and pegylated alpha-2a interferon) that are beneficial only to a subset of infected individuals (Asselah et al, 2007; Lam et al, 2011; Lok et al, 2007; Papatheodoridis and Hadziyannis, 2004; Papatheodoridis et al, 2012; Qiu et al, 2013). For comparison, unlike HBV, anti-HIV therapies work against four different kinds of virus-specific targets.…”

Section: Introductionmentioning

confidence: 99%

Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks

et al. 2015

View full text Add to dashboard Cite

Woodchuck hepatitis virus (WHV) is often used as surrogate to study mechanism of HBV infection. Currently, most infections are conducted using strains WHV7 or WHV8 that have very high sequence identity. This study focused on natural strain WHVNY that is more genetically distant from WHV7. Three naive adult woodchucks inoculated with WHVNY developed productive acute infection with long lasting viremia. However, only one of two woodchucks infected with WHV7 at the same multiplicity demonstrated productive liver infection. Quantification of intracellular WHV RNA and DNA replication intermediates; percentages of core antigen-positive hepatocytes; and serum relaxed circular DNA, showed that strains WHVNY and WHV7 displayed comparable replication levels and capacities to induce acute infection in naive adult woodchucks. Strain WHVNY was therefore validated as valuable reagent to analyze the mechanism of hepadnavirus infection, especially in co- and super-infection settings, which required discrimination between two related virus genomes replicating in the same liver.

show abstract

“…PCR amplification was performed using a similar method to the literature we described previously. 50 Briefly, the human colorectal cell lines (LOVO for wild-type p53 and SW620 for mutant p53 ) were cultured at 37 °C in Ham's F12K liquid medium supplemented with 10% fetal calf serum (FCS). The harvested cells (about10 7 ) were used to extract genomic DNA using the TaKaRa MiniBEST Universal Genomic DNA Extraction Kit Ver.5.0 (Takara Biotechnology).…”

Section: Methodsmentioning

confidence: 99%

A Biofunctional Molecular Beacon for Detecting Single Base Mutations in Cancer Cells

Dong

Wang

et al. 2016

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

The development of a convenient and sensitive biosensing system to detect specific DNA sequences is an important issue in the field of genetic disease therapy. As a classic DNA detection technique, molecular beacon (MB) is often used in the biosensing system. However, it has intrinsic drawbacks, including high assay cost, complicated chemical modification, and operational complexity. In this study, we developed a simple and cost-effective label-free multifunctional MB (LMMB) by integrating elements of polymerization primer, template, target recognition, and G-quadruplex into one entity to detect target DNA. The core technique was accomplished by introducing a G-hairpin that features fragments of both G-quadruplex and target DNA recognition in the G-hairpin stem. Hybridization between LMMB and target DNA triggered conformational change between the G-hairpin and the common C-hairpin, resulting in significant SYBR-green signal amplification. The hybridization continues to the isothermal circular strand-displacement polymerization and accumulation of the double-stranded fragments, causing the uninterrupted extension of the LMMB without a need of chemical modification and other assistant DNA sequences. The novel and programmable LMMB could detect target DNA with sensitivity at 250 pmol/l with a linear range from 2 to 100 nmol/l and the relative standard deviation of 7.98%. The LMMB could sense a single base mutation from the normal DNA, and polymerase chain reaction (PCR) amplicons of the mutant-type cell line from the wild-type one. The total time required for preparation and assaying was only 25 minutes. Apparently, the LMMB shows great potential for detecting DNA and its mutations in biosamples, and therefore it opens up a new prospect for genetic disease therapy.

show abstract

Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors

Cited by 17 publications

References 163 publications

Research review on the pharmacological effects of astragalosideIV

Research review on the pharmacological effects of astragalosideIV

Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks

A Biofunctional Molecular Beacon for Detecting Single Base Mutations in Cancer Cells

Contact Info

Product

Resources

About